CuroTis key facts
as of Oct 2026- Developer of a tissue engineering technology designed for novel therapeutic options for vascular surgery.
- CuroTis is valued at approximately $15.7M as of Oct 2026 (last reported valuation).
- It has raised $4.4M; the latest was Later Stage VC ($1.1M) in Jan 2025.
- Notable investors include High-Tech Gründerfonds, Rijksdienst voor Ondernemend Nederland, Limburg Development and Investment Company, Brightlands Venture Partners, GIMIC Ventures — 7 tracked in total.
- Status: Privately Held (backing).
CuroTis's last reported valuation, Jan 2025. Nothing priced has surfaced since.
- ·Watch CuroTis: the Monday email on marks, rounds and moves
CuroTis funding rounds
No funding rounds for CuroTis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
CuroTis valuation
CuroTis's last reported valuation was $15.7 million in Jan 2025. No priced round, secondary trade or fund mark has surfaced since.
CuroTis investors
7 investors are on record for CuroTis, including High-Tech Gründerfonds, Rijksdienst voor Ondernemend Nederland, Limburg Development and Investment Company and Brightlands Venture Partners.
About CuroTis
Developer of a tissue engineering technology designed for novel therapeutic options for vascular surgery. The company's platform uses a synthetic rod with a specialized surface that is inserted under the skin, inducing the body to form a tissue capsule that matures into a functional blood vessel that is used as a vascular access site for hemodialysis, enabling physicians to create autologous blood vessels that are protected from foreign materials.
- Sector
- Healthcare
- HQ
- Maastricht, Netherlands
- Founded
- 2016
- Employees
- 6
- Website
- curotis.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.